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Background: Nutrients such as ω-3 fatty acids including fish oil components eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) suppress the growth and promote apoptosis of tumor cells, improve immune function
and reduce the effects of systemic inflammatory response syndrome. We sought to investigate the effect of ω-3 fish oil
fat emulsion-based parenteral nutrition (PN) on nutritional state, immune function, inflammatory reaction, expression of
tumor factors and complication incidence in patients after surgical resection of gastric cancer.
Methods: Forty-eight patients after surgical operation of gastric tumor in hospital were randomly divided into the
control group and intervention group. Patients in both groups were treated with iso-nitrogen and iso-caloric parenteral
nutrition support. In addition, the intervention group received ω-3 fish oil fat emulsion and the control group received
soybean oil. The indicators of nutrition, immune function and inflammation in the two groups were detected on the
day before the operation and postoperative day 6. The rate of complication was compared between the two groups.
Results: There was no significant difference in nutritional state, liver function and renal function between the two
groups (P > 0.05). However, the levels of inflammatory markers were significantly decreased (P < 0.01), and the rate of
complication was also decreased in the intervention group as compared with the control group.
Conclusions: ω-3 fish oil fat emulsion-based parenteral nutrition alleviates the inflammatory reaction and reduces the
rate of inflammatory complications.
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Parenteral nutritionBackground
Omega-3 polyunsaturated fatty acids including fish oil
components eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA) are essential for humans as they
cannot be synthesized by the human body. There have
been an increasing number of studies on immune nutri-
tion and cancer therapy over the recent years, and pre-
liminary data suggest that EPA and DHA suppress the
growth and promote apoptosis of tumor cells, as well as
improve immune function and reduce the effects of* Correspondence: caiqingpingwcwk@163.com
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unless otherwise stated.systemic inflammatory response syndrome [1-5]. A re-
cent survey revealed that the content of polyunsatur-
ated fatty acids is likely inadequate in the regular diet of
Chinese [6]. A randomized controlled study evaluated
the effect of omega-3 fatty acid-supplemented total paren-
teral nutrition (TPN) on the clinical outcomes of patients
with hepatitis B virus (HBV)-associated hepatocellular car-
cinoma (HCC) showed that postoperative administration
of omega-3 fatty acid reduced infection and improved
postoperative hepatic function recovery [7]. Short-term
pre-operative infusion of fish oil alone has been shown to
improve the postoperative immune response of gastro-
intestinal cancer patients but exhibited no apparent effect
on postoperative infections or length of intensive care unit. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient demographics and baseline characteristics
Variables The control group The intervention group P
Number 20 26
Sex ratio (M:F) 11:9 15:11 >0.05
Age (years)* 59(36–74) 50.5(29–75) >0.05
Height (cm) 166.5(150–185) 168(155–183) >0.05





I 11 13 >0.05
II 9 13
*Values are median (range).
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ated n-3 PUFA-enriched parenteral nutrition (PN) regi-
mens in elective surgical and ICU patients and showed
that these regimens are safe and effective in reducing the
infection rate and hospital/ICU stay in surgical and ICU
patients [9].
The above findings prompted us to speculate that f ω-3
fish oil fat emulsion-supplemented PN could be beneficial
to the overall functional recovery of gastric tumor patients.
Here, we designed a prospective, randomized, single-
blinded control clinical trial to investigate the effect of ω-3
fish oil fat emulsion-supplemented PN on nutritional state,
immune function, inflammatory reaction, expression of
tumor factors and complication incidence in patients after
surgery of gastric tumors.
Methods
Patient selection
This prospective, randomized, controlled, single center
study was carried out at the authors’ affiliated hospital
between May 2007 and March 2008. The study protocol
was approved by the university and hospital ethics com-
mittees and written informed consent was obtained from
all study subjects or their legal surrogates. The study
was carried out in accordance with the Helsinki Declar-
ation. Complete history was taken and physical examina-
tions were carried out. General assessment of nutritional
status included measurements of body height, body weight
and body mass index (BMI) (kg/m2). Exclusion criteria for
the selection of patients included: (1) age < 18 or > 75 years;
(2) BMI < 16 or > 30 kg/m2; (3) hepatic insufficiency
(Child–Pugh grade B or above); (4) abnormal renal function
(serum creatinine > 3 mg/dL); (5) ongoing infections and
fever in the preceding month; (6) major gastrointestinal dis-
ease such as Crohn’s disease; (7) autoimmune disorders,
steroid treatment, and medication which could modulate
metabolism or body weight; (8) pregnancy or breast-
feeding; (9) received total parenteral support 2 months be-
fore operation; (10) severely malnourished (weight loss of
10% of body weight during the previous 6 months).
Nutrition
Postoperatively, all patients received TPN for at least 6
consecutive days through an indwelling central venous
catheter. These patients were randomly divided into the
intervention (26 patients) and control (26 patients) group.
Both groups were given parenteral nutrition consisting of
104–125 kJ/kg/d of calories for energy with glucose and
fat emulsion as the main sources of energy. Fat emulsion
intralipid (20% Intralipid, Sino-Swed Pharmaceutical Corp.
Ltd.) made up 35–50% of the total calories provided and
0.15–0.20 g/(kg d) of nitrogen was provided using 8.5%
Novamin® (Sino-Swed Pharmaceutical Corp. Ltd.). Glu-
cose and exogenous insulin were provided at a ratio of 6:1,along with vitamins, water, electrolytes and trace elements
via a peripheral vein or central venous infusion for 10 to
12 hours. Finger blood sugar was monitored every 4–
6 hours, and if blood sugar was high, insulin was given to
control glucose level. Patients in both groups received
about 2800 mL liquid per day and without any intake per
oral. In all patients, prophylactic antibiotic treatment was
given for 3 to 4 days postoperatively (Cefuroxime, 2 g b.i.d.
intravenously (i.v.) and metronidazole 500 mg b.i.d. i.v.). In
the control group (Group I), the fat emulsion used was
omega-6 lipid (20% Intralipid, Sino-Swed Pharmaceutical
Corp. Ltd.). In the intervention group (Group II), the
omega-6 lipid content of TPN was partially replaced by
omega-3 PUFA (10% Omegaven, Sino-Swed Pharmaceut-
ical Corp. Ltd.) up to 0.2 g/kg body weight daily; therefore,
the omega-3/omega-6 ratio was 1:4. Calculated by body
mass, nutrition in both groups was isonitrogenous and
isocaloric.
Blood sample assays
In the morning before operation and on postoperative day
6, blood sample assays were collected from all the patients.
Routine blood test and biochemistry analysis including total
protein (TP), albumin (ALB), pre-albumin (PA), retinol
binding protein (RBP), transferrin (TF), serum total choles-
terol (TC), total bilirubin (TBil), alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and creatinine
(Cr) were immediately performed at the Department of
Clinical Chemistry, Shanghai Changzheng Hospital accord-
ing to standard laboratory procedures.
Percentage of CD3+, CD4+, and CD8+ lymphocytes
were analyzed by flow cytometry at the Department of
Clinical Chemistry, Shanghai Changzheng Hospital ac-
cording to standard laboratory procedures.
Serum was also separated from 3 mL blood from each
patient at 4°C and centrifuged at 3000 rpm for 5 minutes.
Serum from each patient was stored at -20°C and used
to run an ELISA assay for quantification of serum IL-1β,
Table 2 Comparison of pre- and postoperative nutritional indices of the study patients
Indices Preoperative Postoperative
Study group Control group P Study group Control group P
TP 68.97 ± 6.38 68.35 ± 7.66 0.77 64.58 ± 6.14* 64.88 ± 6.47 0.87
ALB 41.52 ± 3.89 39.26 ± 4.52 0.08 37.17 ± 6.16* 36.07 ± 4.63* 0.49
PA 242.96 ± 66.25 218.03 ± 50.36 0.15 191.42 ± 55.31* 197.63 ± 41.65 0.67
RBP 0.034 ± 0.012 0.028 ± 0.010 0.07 0.049 ± 0.058 0.032 ± 0.011 0.15
TF 2.577 ± 0.63 2.447 ± 0.48 0.44 1.934 ± 0.45* 1.93 ± 0.42* 0.97
TC 3.84 ± 0.61 4.22 ± 1.06 0.16 3.29 ± 0.72* 3.85 ± 1.64 0.17
TP, total protein; ALB, albumin; PA, pre-albumin; RBP, retinol binding protein; TF, transferrin; TC, total cholesterol.
*Indicates significant difference vs. the preoperative value in the same group.
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(American Bio-rad) in accordance with standard operat-
ing instructions.
Patient monitoring
Postoperative complications including respiratory tract
infections (if chest radiographic examination showed
new or progressive infiltrates and temperature increases
above 38.5°C), urinary tract infection (if urine culture
showed at least 105 colonies of a pathogen), abdominal
abscess (if patient reported abdominal pain and high
white blood cell count, and ultrasound examination de-
tected an anechoic area in the abdomen), and wound
complications, such as fistula and/or wound infection
were assessed by the same investigator surgeon and re-
corded accordingly.
Statistical analysis
Mean ± SD of each value was obtained and the difference
between the intervention and control groups for each
value tested for statistical significance using the software
SPSS (version 13.0). Analysis of variance or Student’s t-test
or chi-square test was used in statistical analyses. P < 0.05
was considered statistically significant.Results
Patient demographic and baseline characteristics
Fifty-two patients with gastric tumor were enrolled in-
cluding 26 males and 26 females aged between 29 andTable 3 Comparison of the pre- and postoperative immune in
Indices Preoperative
The intervention group The control group P
TLC 1.31 ± 0.42 1.28 ± 0.41 0.7
CD3 67.14 ± 8.58 65.74 ± 9.20 0.5
CD4 42.48 ± 8.91 38.92 ± 9.80 0.2
CD8 22.69 ± 8.85 23.92 ± 7.57 0.
CD4/CD8 2.34 ± 1.19 1.90 ± 1.06 0.2
TLC, total T lymphocyte cells.75 years (median, 53.5 years). Six patients were excluded
from the control group because of incomplete data and
as a result there were 20 patients in the control group.
All patients in the study did not suffer any severe com-
plications or death. During hospitalization, the vital signs
of both groups were stable. No adverse effects associated
with parenteral nutritional support were observed such
as parenteral nutrition-associated liver disease (PNALD),
infection, phlebitis, and glucose intolerance. Patient
demographic and baseline characteristics are shown in
Table 1.Changes in the nutritional indices
There were no significant differences (P > 0.05) between
the two patient groups in nutritional indicators such as TP
(g/L), ALB (g/L), PA (mg/L), RBP (g/L), TF (g/L) and TC
(mmol/L) before and after operation as shown in Table 2.
However, TP, ALB, PA, TF and TC were significantly re-
duced after surgery in the intervention group, and ALB
and TF were significantly decreased in the control group
(indicated by * in Table 2).
Changes of immunologic parameters
There were no significant differences (P > 0.05) between
the two groups in immunologic indicators such as total T
lymphocyte cells (TLC, ×109/L), CD3(%), CD4(%), CD8
(%) and CD4/CD8 positive lymphocytes before surgery.
Postoperatively, all these parameters remained comparable
(Table 3). Comparing the preoperative and postoperativedices of the study patients
Postoperative
The intervention group The control group P
01 1.12 ± 0.37 1.08 ± 0.36 0.438
99 64.71 ± 10.51 66.07 ± 7.64 0.615
11 44.23 ± 9.46 41.74 ± 8.67 0.358
61 19.85 ± 7.36 21.47 ± 5.94 0.414
12 2.61 ± 1.33 2.16 ± 1.00 0.198
Table 4 Comparison of the pre- and postoperative inflammatory indices of the study patients
Indices Preoperative Postoperative
Study group Control group P Study group Control group P
WBC 5.26 ± 3.09 4.76 ± 1.37 0.331 7.42 ± 2.79 5.95 ± 1.46* 0.025*
CRP 3.98 ± 2.17 5.64 ± 9.83 0.269 30.90 ± 31.17* 33.62 ± 7.36* 0.733
IL-1β 201.51 ± 16.06 196.38 ± 21.90 0.422 302.32 ± 37.61* 332.61 ± 35.34* 0.011*
IL-6 15.53 ± 61.57 16.56 ± 62.04 0.950 14.35 ± 45.95 48.25 ± 67.49* 0.007*
TNF-α 15.31 ± 52.61 19.77 ± 52.38 0.889 12.05 ± 60.31 53.56 ± 75.23* 0.005*
CRP. C-reactive protein; WBC, white blood cells.
*Indicates significant difference vs. the preoperative value in the same group.
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ther the control or intervention group.
Inflammatory response
There were no statistical differences (P > 0.05) between the
two groups of patients in the five inflammatory indicators –
WBC (×109/L), CRP (mg/L), IL-1β (pg/mL), IL-6 (pg/mL)
and TNF-α (pg/mL) before surgery. The differences in
WBC, IL-1β, IL-6 and TNF-α between the 2 groups post
surgery were statistically significant (P < 0.05), as shown in
Table 4. Comparing the preoperative and postoperative
data, WBC, IL-6 and TNF-α of the intervention group did
not increase, whereas those of the control group had a sig-
nificant increase (indicated by * in Table 4). CRP and IL-1β
of both groups increased significantly after surgery.
Expression of tumor-related factors
There was no statistical difference between the two
groups in VEGF (pg/mL) and IGF-1 (ng/mL) before and
after surgery (P > 0.05), as shown in Table 5. Comparing
the pre-surgery and post-surgery data, VEGF and IGF-1
of both groups showed a trend of decrease, but no sta-
tistically significant difference was observed.Postoperative infectious complications
There were three cases of incisional wound infection, one
case of abdominal infection, one case of urinary infection
and one case of pulmonary infection in the control group;
and there was one case of incisional wound infection and
one case of pulmonary infection in the intervention group.
Although the comparison of each kind of complication
did not shown significant difference between the twoTable 5 Comparison of the preoperative and postoperative tu
Indices Preoperative
The intervention group The control group P
VEGF 346.21 ± 366.55 271.08 ± 276.68 0.3
IGF-1 403.31 ± 28.50 393.81 ± 34.53 0.3groups, the combined incidences of complications in the
control group was significantly higher than that of the
intervention group, as shown in Table 6.Discussion
Cancer is a wasting disease and cancer patients are at a
high risk of malnutrition. Due to the possibility that paren-
teral nutrition may stimulate tumor growth and prolifera-
tion, parenteral nutritional support for tumor patients is
controversial [10]. However, it is clear that nutritional sup-
port is important for patients undergoing surgery or re-
ceiving chemotherapy, radiation therapy and other cancer
treatments, which also helps maintain the body’s im-
munity. Appropriate perioperative nutritional support is
important in improving the nutritional status of the
body, maintaining the structure and function of the or-
gans, reducing the incidence of surgical mortality and
postoperative complications, and improving the pa-
tient’s quality of life [11]. It also provides a good plat-
form for the body to withstand the next round of
treatment [11]. Our clinical trial suggests that a stand-
ard calorie parenteral nutrition program such as the
one used in the current trial can effectively maintain the
nutritional status of patients post surgery.
ω-3 fish oil is made up of the fatty acids EPA and
DHA, which the body itself can only synthesize a very
small amount. EPA and DHA can increase the amount
of phospholipid omega-3 in cell membranes, while re-
ducing inflammatory eicosane generation by increasing
the amount of non-inflammatory eicosane competing in
the arachidonic acid synthetic pathway. The release of
antibodies and the phagocytic activity of macrophages aremor factors of the study patients
Postoperative
The intervention group The control group P
89 200.35 ± 183.61 177.30 ± 167.83 0.622
16 369.13 ± 53.23 341.87 ± 75.27 0.119
Table 6 Comparison of postoperative infectious complications of the study patients
The control group The intervention group Fisher’s exact test (two-tailed)
Incisional wound infection 3/20 1/26 P = 0.303
Abdominal infection 1/20 0/26 P = 0.435
Urinary infection 1/20 0/26 P = 0.435
Pulmonary infection 1/20 0/26 P = 0.435
Total complications 6/20 1/26 P = 0.033
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pro-inflammatory cytokines IL-1, IL-6 and TNF-α. As
shown in our study in Table 4, IL-6 and TNF-α were only
increased in the control group postoperatively, but not in
the intervention group. The use of omega-3 fat emulsion
can also increase the release of anti- inflammatory cyto-
kines IL-10, IL- 13, and TGB-β, thus blocking the body’s
excessive inflammatory response and reducing the inci-
dence of Systemic Inflammatory Response Syndrome
(SIRS) and Multiple Organ Dysfunction Syndrome
(MODS). The mortality of patients was therefore de-
creased and the prognosis of patients improved after
major abdominal surgery, and in patients with periton-
itis and abdominal sepsis and other conditions [12]. In
our study, we found a significantly higher chance of
postoperative infections in the control group (Table 6),
which is consistent with the higher postoperative WBC
levels in the control group. Together, our data suggests
that ω-3 fish oil fat emulsion supplementation can re-
duce the body’s pro-inflammatory reaction after surgery,
contributing to lower incidences of postoperative infec-
tion and aiding in the early recovery of patients.
Current research on the effects of ω-3 fatty acids on im-
mune function revolves around their effects on cytokines,
adhesion molecules, differentiation antigen receptor ex-
pression, free radicals, peroxides, antibody production,
lymphocyte proliferation, antigen-presenting cell function
and natural killer cell cytotoxicity [13]. The role of ω-3
fatty acids in regulating the levels of these immune factors
in the body can therefore lead to enhanced immune func-
tion [13]. Studies also suggest that ω-3 fatty acids may
alter the lipid environment of membrane micro-lipids,
shifting the receptor protein to a non-functional region,
thereby generating immune-modulatory effects [14]. ω-3
fatty acids can also play its role in the immune system by
modulating dendritic cells (DCs) [15].
Alanine aminotransferase and aspartate aminotransfer-
ase were increased in both groups 6 days post surgery,
but the increase was to a lesser extent in the interven-
tion group, which stayed within the normal range. This
indicates that ω-3 fish oil fat emulsion may decrease the
amount of hepatic damage resulting from gastric cancer
surgery. This may be related to the role of ω-3 fatty
acids in increasing liver blood perfusion and reducingintestinal bacterial translocation [16]; as well as their
ability to reduce the release of prostaglandin E2
(PGE2), leukotriene B4 (LTB4) and platelet activating
factor, resulting in the inhibition of L-1β, IL-2 and
TNF-α mRNA expression, thereby blocking the ex-
cessive inflammatory response to protect the function
of vital organs [17].
In conclusion, ω-3 fish oil fat emulsion-based paren-
teral nutrition promotes the recovery of the immune
function, alleviates inflammation and reduces the rate of
complications in patients with surgically resected gastric
tumors. However, our findings await confirmation from
future prospective controlled studies on a larger patient
population.
Abbreviations
ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase;
Cr: Creatinine; CRP: C-Reactive protein; DHA: Docosahexaenoic acid;
EPA: Eicosapentaenoic acid; IL-1: Interleukin-1; LTB4: Leukotriene B4;
MODS: Multiple organ dysfunction ssyndrome; PUFA: Polyunsaturated fatty acid;
PA: Pre-albumin; PGE2: Prostaglandin E2; PN: Parenteral nutrition; RBP: Retinol
binding protein; SIRS: Systemic inflammatory response syndrome;
TB4: Leukotriene B4; TBil: Total bilirubin; TC: Serum total cholesterol;
TF: Transferrin; TNF-α: Tumor necrosis factor-alpha; TP: Total protein L;
TPN: Triphospho-pyridine-nucleotide.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All of the authors have made substantial contributions to the study ZW:
(1) the conception and design of the study, acquisition of data, analysis and
interpretation of data, (2) drafting the article. (3) final approval of the version
to be submitted. WW: (1) the conception and design of the study, and
interpretation of data, (2)revising the manuscript critically for important
intellectual content, (3) final approval of the version to be submitted. JC:
(1) interpretation of data, (2) revising the manuscript critically for important
intellectual content, (3) final approval of the version to be submitted. DY:
(1) the conception and design of the study, acquisition of data, analysis and
interpretation of data, (2) revising the manuscript critically for important
intellectual content, (3) final approval of the version to be submitted. RY:
(1) interpretation of data, (2) revising the manuscript critically for important
intellectual content, (3) final approval of the version to be submitted. QC:
(1) the conception and design of the study, acquisition of data, analysis and
interpretation of data, (2) revising the manuscript critically for important
intellectual content, (3) final approval of the version to be submitted.
All authors read and approved the final manuscript.
Acknowledgements
We thank all the people who gave us help in the research.
Received: 10 October 2013 Accepted: 17 March 2014
Published: 24 March 2014
Wei et al. Nutrition Journal 2014, 13:25 Page 6 of 6
http://www.nutritionj.com/content/13/1/25References
1. Fukui M, Kang KS, Okada K, Zhu BT: EPA, an omega-3 fatty acid, induces
apoptosis in human pancreatic cancer cells: role of ROS accumulation,
caspase-8 activation, and autophagy induction. J Cell Biochem 2013,
114:192–203.
2. Hjorth E, Zhu M, Toro VC, Vedin I, Palmblad J, Cederholm T, Freund-Levi Y,
Faxen-Irving G, Wahlund LO, Basun H, Eriksdotter M, Schultzberg M:
Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-
related amyloid-β42 by human microglia and decrease inflammatory
markers. J Alzheimers Dis 2013, 35:697–713.
3. Miles EA, Calder PC: Influence of marine n-3 polyunsaturated fatty acids
on immune function and a systematic review of their effects on clinical
outcomes in rheumatoid arthritis. Br J Nutr 2012, 107(Suppl 2):S171–S184.
4. Singer P, Shapiro H, Theilla M, Anbar R, Singer J, Cohen J: Anti-
inflammatory properties of omega-3 fatty acids in critical illness: novel
mechanisms and an integrative perspective. Intensive Care Med 2008,
34:1580–1592.
5. Oz HS, Chen TS, Neuman M: Nutrition intervention: a strategy against systemic
inflammatory syndrome. JPEN J Parenter Enteral Nutr 2009, 33:380–389.
6. Yu M, Gao Q, Wang Y, Zhang W, Li L, Wang Y, Dai Y: Unbalanced omega-6/
omega-3 ratio in red meat products in China. J Biomed Res 2013, 27:366.
7. Wu Z, Qin J, Pu L: Omega-3 fatty acid improves the clinical outcome of
hepatectomized patients with hepatitis B virus (HBV)-associated
hepatocellular carcinoma. J Biomed Res 2012, 26:395–399.
8. de Miranda Torrinhas RS, Santana R, Garcia T, Cury-Boaventura MF, Sales
MM, Curi R, Waitzberg DL: Parenteral fish oil as a pharmacological agent
to modulate post-operative immune response: a randomized, double-
blind, and controlled clinical trial in patients with gastrointestinal cancer.
Clin Nutr 2013, 32:503–510.
9. Pradelli L, Mayer K, Muscaritoli M, Heller AR: n-3 fatty acid-enriched paren-
teral nutrition regimens in elective surgical and ICU patients: a meta-
analysis. Crit Care 2012, 16:R184 [Epub ahead of print].
10. Cozzaglio L, Balzola F, Cosentino F, DeCicco M, Fellagara P, Gaggiotti G,
Gallitelli L, Giacosa A, Orban A, Fadda M, Gavazzi C, Pirovano F, Bozzetti F:
Outcome of cancer patients receiving home parenteral nutrition.
J Parenter Enteral Nutr 1997, 21:339.
11. Nordenstrom J, Thorme A: Benefits and complications of parenteral
nutritional support. Eur J Clin Nutr 2000, 48:53.
12. Heller AR, Rössler S, Litz RJ, Stehr SN, Heller SC, Koch R, Koch T: Omega-3
fatty acids improve the diagnosis-related clinical outcome. J Crit Care
Med 2006, 34:972.
13. Mayer K, Schaefer MB, Seeger W: Fish oil in the critically ill: from
experimental to clinical data. Curr Opin Clin Nutr Metab Care 2006, 9:140–148.
14. Li Q-r, Tan L, Wang C, Ma J, Guowang X, Li J: Polyunsaturated fatty acids
(20: 5 n–3) changes of lipid composition in Jurkat T cell membrane
subdomains. Acta Nutrimenta Sinica 2006, 28:124–127.
15. Wang Z, Li Q, Hao Q, Li Y, Li N, Li J: Effect of ω-3 polyunsaturated fatty
acids on phenotypes and functions of dendritic cells. Chinese J Exp Surg
2005, 22:1427–1429.
16. Pscheidl E, Schywalsky M, Tschaikowsky K, Böke-Pröls T: Fish oil -supplemented
parenteral diets normalize splanchnic blood flow and improve killing of
translocated bacteria in a low dose endotoxin rat mode. J Crit Care Med
2000, 28:1489–1496.
17. Koch T, Heller AR: Benefits of ω-3 fatty acids in parenteral nutrition. J Clin
Nutr S 2005, 1:17–24.
doi:10.1186/1475-2891-13-25
Cite this article as: Wei et al.: A prospective, randomized, controlled study
of ω-3 fish oil fat emulsion-based parenteral nutrition for patients following
surgical resection of gastric tumors. Nutrition Journal 2014 13:25.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
